AB 1003 - Asklepios BioPharmaceutical
Alternative Names: AB-1003 - Asklepios BioPharmaceutical; LION-101Latest Information Update: 02 Mar 2023
At a glance
- Originator Asklepios BioPharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Limb girdle muscular dystrophies
Most Recent Events
- 27 Feb 2023 Phase-I/II clinical trials in Limb girdle muscular dystrophies (In adults, In the elderly) in USA (IV) (NCT05230459)
- 27 Feb 2023 AB 1003 - Asklepios BioPharmaceutical receives Orphan Drug status for Limb girdle muscular dystrophies in European Union
- 28 Jun 2021 AB 1003 receives Fast Track designation for Limb girdle muscular dystrophies [IV] in USA